 - Patients that are determined to have a rare cancer with unknown primary site are eligible under cohort 32 tumor of unknown primary cancer of unknown primary; CuP, provided that there is histologic documentation of metastatic malignancy with no discernible primary site identified from histopathologic review, physical exam and associated cross-sectional imaging of the chest, abdomen, and pelvis 